These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 4647090)

  • 1. [Preparation and in vivo control of the sustained release of a delayed-action preparation: 7-(2-hydroxy-3-((2-hydroxyethyl)-methylamino)-propyl)-thiophylline nicotinate].
    Belligno A; Zanotti A; Girlando M; Ottaviano G
    Boll Chim Farm; 1972 Aug; 111(8):500-6. PubMed ID: 4647090
    [No Abstract]   [Full Text] [Related]  

  • 2. Tablets of 7-(3'-(methylhydroxylethylamino)-2'-hydroxypropyl)-theophylline nicotinate with prolonged action. II. Retardation of the drug release by polymer coating of tablets.
    Chodkowska-Granicka B; Pawlak Z; Pawlak E; Surowiecki J
    Acta Pol Pharm; 1972; 29(6):618-22. PubMed ID: 4670139
    [No Abstract]   [Full Text] [Related]  

  • 3. [Nicotinic acid blood levels after application of xanthinolnicotinate in a new galenic retard preparation].
    Brenner G
    Arzneimittelforschung; 1975 Feb; 25(2):237-40. PubMed ID: 1173039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative bioavailability of 2 oral theophylline sustained-release preparations].
    Tritthart W; Lücker PW; Fáy E; Buchebner J
    Arzneimittelforschung; 1983; 33(11):1603-6. PubMed ID: 6686457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ON THE TREATMENT OF APOPLEXY WITH COMPLAMIN (7-(2-HYDROXY-3-(N-2-HYDROXYETHYL-N-METHYLAMINO)PROPYL)THEOPHYLLINE NICOTINATE].
    FRUHMANN H
    Med Welt; 1963 Oct; 41():2084-7. PubMed ID: 14134155
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state].
    Bochsler HP; Meyer UA
    Schweiz Med Wochenschr; 1982 Nov; 112(47):1702-10. PubMed ID: 7178872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo-in vitro correlations with sustained-release theophylline preparations.
    Ritschel WA; Koch HP; Alcorn GJ
    Methods Find Exp Clin Pharmacol; 1984 Oct; 6(10):609-18. PubMed ID: 6513678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative bioavailability and release pattern of whole and halved sustained-release theophylline tablets.
    Leeds NH; Gal P; Purohit AA; Walter JB
    Clin Pharm; 1982; 1(2):163-4. PubMed ID: 7185516
    [No Abstract]   [Full Text] [Related]  

  • 9. Abnormal absorption of a sustained-release theophylline preparation.
    Newman LJ; Richards W; Church JA; Borzy MS
    Ann Allergy; 1980 Aug; 45(2):95-6. PubMed ID: 7406253
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis.
    Valet SB; Schwartz RH; Brooks JG
    Ann Allergy; 1983 Mar; 50(3):161-5. PubMed ID: 6829982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time and pH dependent colon specific, pulsatile delivery of theophylline for nocturnal asthma.
    Mastiholimath VS; Dandagi PM; Jain SS; Gadad AP; Kulkarni AR
    Int J Pharm; 2007 Jan; 328(1):49-56. PubMed ID: 16942847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [2-hydroxy-3-(N-2-hydroxyethyl-N-methylamino)-propyl]-1,3-dimethylxanthine nicotinate].
    LENNARTZ H
    Arzneimittelforschung; 1962 Jul; 12():675-9. PubMed ID: 14463992
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of Nuelin-SR 250 mg in asthmatic children: a new sustained-release theophylline.
    Mitchell EA; Liang AY
    N Z Med J; 1980 Aug; 92(665):91-3. PubMed ID: 6933343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
    Steinijans VW; Zech K; Fischer R
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Release, absorption and elimination of theophylline from fast and slowly released oral formulations].
    Frömming KH; Schwabe L; Staib AH; Rietbrock N; Lassmann A; Molz KH; Schuppan D; Siebert-Weigel M; Voegele D
    Arzneimittelforschung; 1983; 33(3):446-52. PubMed ID: 6683521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinogen turnover during the treatment with xantinol nicotinate.
    Cultrera G; Giarola P; Gibelli A; Baldoni E; Cuttin S; Galetti G; Serenth'a P
    Arzneimittelforschung; 1971 Jul; 21(7):954-7. PubMed ID: 5109508
    [No Abstract]   [Full Text] [Related]  

  • 17. [Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)].
    Schneider GF; Heese GU; Huber HJ; Janzen N; Jünger H; Moser C; Stanislaus F
    Arzneimittelforschung; 1981; 31(9):1489-97. PubMed ID: 7197962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and evaluation of matrix and two layered sustained release suppositories of theophylline.
    Maity S; Sa B; Bandyopadhyay AK
    Boll Chim Farm; 2001; 140(6):462-6. PubMed ID: 11822240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tablets of 7-(3'-(methylhydroxyethylamino)-2'-hydroxypropyl)-theophylline nicotinate with delayed action. I. Moderation of the release of the active substance by some additives].
    Pawlak E; Chodkowska-Granicka B; Surowiecki J
    Acta Pol Pharm; 1971; 28(1):43-7. PubMed ID: 5577811
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioavailability of sustained-release theophylline formulations.
    Bonora Regazzi M; Rondanelli R; Vidale E; Cristiani D
    Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):245-51. PubMed ID: 6862729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.